They will be a force in the phosphate binder market. That leaves a smaller share of the pie for everyone else.
"Phosphate binder PA21: Vifor Pharma enters into partnership with Kissei Pharmaceutical for Japan.
Friday, 17 September 2010
Based on very promising results from the Phase II study and a clear unmet clinical need, Kissei Pharmaceutical will become the partner of Vifor Pharma for development and commercialisation of PA21 for Japan.
_Vifor Pharma, the Pharma business sector of the Galenica Group, has entered into an agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialise its novel iron-based phosphate binder – PA21 – in Japan. This collaboration is a further step in the strategy of developing and commercialising PA21 with strong regional partners. In June 2010, a first partnership was announced with Fresenius Medical Care (FMC). FMC will support the phase III study in the US and will become the commercial partner for Vifor Pharma in North America.
_PA21 covers an unmet clinical need in the phosphate binder market. Dialysis patients suffer from hyperphosphatemia and nephrologists agree that this is a key risk factor for cardiovascular mortality. Despite the fact that almost all dialysis patients are treated with phosphate binders less than 50% reach their target phosphate levels. Therefore, the market needs new products. PA21 has an ideal target product profile to serve these needs."